Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

BMO Capital Maintains Hold Rating on Amgen with Target Price of $450

Guavy AI Editorial Team
Instruments
AMGN
Share

BMO Capital analyst Evan Seigerman has maintained his hold rating for Amgen (AMGN.US) and set its target price at $450. This decision is based on Seigerman's analysis, which has a success rate of 57.9% over the past year.

The average return from his recommendations during this period was 10.0%. TipRanks data evaluates analysts' performance using a star rating system. Seigerman currently holds 3 stars based on his total success rate and average return.

More on Stocks

Stocks 3m ago

JPMorgan Chase Ends Substantial Holding in West African Resources Ltd

Stocks 3m ago

JPMorgan Chase Stock Edges Higher Amid Analyst Confidence

Stocks 3m ago

JPMorgan Notifies Siltronic AG of Voting Rights Change

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy